Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

<< Previous

Bullboard Posts

Next >>

Post by SmartPodhotzoneon Jan 04, 2021 10:17pm

136 Views

Post# 32221427

what am i missing here at mice study stage

no where near phase 3 until 2022 0r 23 if all goes well

still at mice study

looks like the new pr company hire really got this pumped up...congrats to thois who held the pump by new pr firm

no worth this vaklue at mice study stage

<< Previous

Bullboard Posts

Next >>

Canopy Growth nears adjusted EBITDA profitability in Q2 2025